Last reviewed · How we verify
Placebo to match mirabegron
Placebo to match mirabegron is a Small molecule drug developed by Astellas Pharma Europe B.V.. It is currently in Phase 3 development for Placebo control for mirabegron trials in overactive bladder.
This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes.
This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes. Used for Placebo control for mirabegron trials in overactive bladder.
At a glance
| Generic name | Placebo to match mirabegron |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inactive substances used in controlled trials to provide a comparator arm and minimize bias. This particular placebo is manufactured to match mirabegron (a beta-3 adrenergic agonist used for overactive bladder) in appearance, taste, and administration route, allowing trial participants and researchers to remain blinded to treatment assignment while evaluating mirabegron's efficacy and safety.
Approved indications
- Placebo control for mirabegron trials in overactive bladder
Common side effects
Key clinical trials
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PHASE4)
- A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (PHASE3)
- A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match mirabegron CI brief — competitive landscape report
- Placebo to match mirabegron updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI
Frequently asked questions about Placebo to match mirabegron
What is Placebo to match mirabegron?
How does Placebo to match mirabegron work?
What is Placebo to match mirabegron used for?
Who makes Placebo to match mirabegron?
What development phase is Placebo to match mirabegron in?
Related
- Manufacturer: Astellas Pharma Europe B.V. — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Placebo control for mirabegron trials in overactive bladder